Relationship of Fat Mass Ratio, a Biomarker for Lipodystrophy, With Cardiometabolic Traits
Diabetes · 01.07.2024 · 73 (7) · 1099-1111
DOI: 10.2337/db23-0575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 12.02.2024. Verfasst von Saaket Agrawal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA. Hauptthemen laut MEDLINE: Biomarkers. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS, Sarnoff Cardiovascular Research Foundation, National Human Genome Research Institute.
Abstract (Originalsprache)
Familial partial lipodystrophy (FPLD) is a heterogenous group of syndromes associated with a high prevalence of cardiometabolic diseases. Prior work has proposed DEXA-derived fat mass ratio (FMR), defined as trunk fat percentage divided by leg fat percentage, as a biomarker of FPLD, but this metric has not previously been characterized in large cohort studies. We set out to 1) understand the cardiometabolic burden of individuals with high FMR in up to 40,796 participants in the UK Biobank and 9,408 participants in the Fenland study, 2) characterize the common variant genetic underpinnings of FMR, and 3) build and test a polygenic predictor for FMR. Participants with high FMR were at higher risk for type 2 diabetes (odds ratio [OR] 2.30, P = 3.5 × 10−41) and metabolic dysfunction–associated liver disease or steatohepatitis (OR 2.55, P = 4.9 × 10−7) in UK Biobank and had higher fasting insulin (difference 19.8 pmol/L, P = 5.7 × 10−36) and fasting triglycerides (difference 36.1 mg/dL, P = 2.5 × 10−28) in the Fenland study. Across FMR and its component traits, 61 conditionally independent variant-trait pairs were discovered, including 13 newly identified pairs. A polygenic score for FMR was associated with an increased risk of cardiometabolic diseases. This work establishes the cardiometabolic significance of high FMR, a biomarker for FPLD, in two large cohort studies and may prove useful in increasing diagnosis rates of patients with metabolically unhealthy fat distribution to enable treatment or a preventive therapy. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
- Department of Medicine, Massachusetts General Hospital, Boston, MA.
- Department of Medicine, Harvard Medical School, Boston, MA.
- MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge Biomedical Campus, Cambridge, U.K.
- Marea Therapeutics, San Francisco, CA.
- Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
ORCID-Profile: Saaket Agrawal
Förderung
- NHGRI NIH HHS
- Sarnoff Cardiovascular Research Foundation
- National Human Genome Research Institute
Zitieren
APA
Agrawal, S., Luan, J., Cummings, B. B., Weiss, E. J., Wareham, N. J., & Khera, A. V. (2024). Relationship of Fat Mass Ratio, a Biomarker for Lipodystrophy, With Cardiometabolic Traits. Diabetes, 73(7), 1099-1111. https://doi.org/10.2337/db23-0575
Vancouver
Agrawal S, Luan J, Cummings BB, Weiss EJ, Wareham NJ, Khera AV. Relationship of Fat Mass Ratio, a Biomarker for Lipodystrophy, With Cardiometabolic Traits. Diabetes. 2024;73(7):1099-1111. doi:10.2337/db23-0575
BibTeX
@article{Agrawal2024,
author = {Agrawal, Saaket and Luan, Jian'an and Cummings, Beryl B and Weiss, Ethan J and Wareham, Nick J and Khera, Amit V},
title = {Relationship of Fat Mass Ratio, a Biomarker for Lipodystrophy, With Cardiometabolic Traits},
journal = {Diabetes},
year = {2024},
volume = {73},
number = {7},
pages = {1099--1111},
doi = {10.2337/db23-0575}
}
EUVIMED